Lithium is making a comeback in psychiatry because new research has fundamentally changed how scientists understand the drug — not just as a mood stabilizer, but as a potential neuroprotective agent that may slow or even prevent Alzheimer’s disease. A landmark study published in Nature in August 2025 revealed that lithium is the only metal significantly reduced in the brains of people with mild cognitive impairment and Alzheimer’s, suggesting that lithium deficiency itself may drive the disease. That finding, combined with growing evidence that low-dose lithium can improve mood and cognition without the side effects of traditional doses, has reignited interest in a medication that many psychiatrists had quietly abandoned in favor of newer, more heavily marketed alternatives. For decades, lithium was the undisputed cornerstone of bipolar disorder treatment.
Then its use fell off a cliff — prescriptions in North America dropped from 27.7% of bipolar patients before 2010 to just 17.1% after, pushed aside by aggressive pharmaceutical marketing of atypical antipsychotics and a medical culture that grew uncomfortable with a drug requiring blood monitoring. But the pendulum is swinging back. A 2017–2022 prescribing study found a modest rebound in lithium prescriptions, and a 2025 expert consensus Delphi study reaffirmed lithium as the gold standard for bipolar disorder management. This article covers the Alzheimer’s research that changed the conversation, why lithium fell out of favor in the first place, what low-dose lithium means for brain health, the suicide prevention evidence that never went away, and what all of this means for patients and families navigating cognitive decline.
Table of Contents
- What New Research Is Driving Lithium’s Comeback in Psychiatry?
- Why Did Psychiatrists Stop Prescribing Lithium in the First Place?
- What Does Low-Dose Lithium Mean for Brain Health and Dementia Prevention?
- How Does Lithium Compare to Other Approaches for Neuroprotection?
- Lithium and Suicide Prevention — The Evidence That Never Went Away
- What the Expert Consensus Now Says About Lithium
- Where Lithium Research Goes From Here
- Conclusion
- Frequently Asked Questions
What New Research Is Driving Lithium’s Comeback in Psychiatry?
The most significant catalyst is the August 2025 Nature paper titled “Lithium Deficiency and the Onset of Alzheimer’s Disease,” conducted by researchers in Boston and Chicago. Previous studies had hinted at a connection between lithium and brain health, but this was the first to demonstrate that endogenous lithium — the lithium naturally present in brain tissue — is dynamically regulated and plays an active role in cognitive preservation during aging. When researchers examined brain tissue from individuals with Alzheimer’s, lithium was the only metal that showed significant depletion compared to healthy controls. This was not about taking lithium supplements; the brain itself appeared to lose its ability to maintain adequate lithium levels as disease set in. The animal model work was equally striking. When researchers reduced cortical lithium levels by approximately 50% in mice, the results were dramatic: markedly increased amyloid-β deposition, accelerated phospho-tau accumulation, pro-inflammatory microglial activation, loss of synapses, axonal damage, myelin degradation, and faster cognitive decline.
In other words, reducing brain lithium reproduced nearly the full spectrum of Alzheimer’s pathology. The mechanism centers on an enzyme called GSK3β — lithium inhibits this kinase, which helps prevent the tau phosphorylation and amyloid buildup that characterize Alzheimer’s. When lithium drops, GSK3β runs unchecked, and the disease cascade begins. Perhaps most encouraging for patients and families, the study also showed that low-dose lithium orotate nearly restored memory and reversed disease markers in aging animals. This is not the same as proving efficacy in humans, and clinical trials are still needed. But the biological mechanism is now well-characterized, and the implications are enormous. A clinical trial (NCT06662526) is currently investigating lithium for prevention of cognitive decline in mood disorder patients — one of the first rigorous tests of whether these animal results translate to people.
Why Did Psychiatrists Stop Prescribing Lithium in the First Place?
The decline of lithium prescribing is one of the more troubling stories in modern psychiatry. Mood stabilizer prescriptions overall fell from 62.3% of bipolar patients between 1997 and 2000 to just 26.4% between 2013 and 2016. Only about 25% of bipolar disorder patients are currently prescribed lithium, despite every major international guideline listing it as a first-line treatment. The drug that a 2025 MDPI review called the reference standard after 75 years of use was being prescribed to barely a quarter of the patients who could benefit from it. Several forces drove this decline. Aggressive marketing by manufacturers of atypical antipsychotics — drugs like quetiapine, aripiprazole, and olanzapine — positioned these newer medications as easier to manage and more modern.
Lithium requires periodic blood monitoring to ensure levels stay in a safe therapeutic range, and many clinicians found this inconvenient or were insufficiently trained in lithium management. The gap between specialists and generalists is particularly wide: primary care doctors are approximately 80% less likely than psychiatrists to prescribe lithium. For patients in rural areas or without easy access to a psychiatrist, this effectively took lithium off the table entirely. However, “newer” has not always meant “better.” The atypical antipsychotics that replaced lithium carry their own serious side effect profiles, including metabolic syndrome, significant weight gain, and diabetes risk. And none of them have lithium’s demonstrated ability to reduce suicide risk or its emerging neuroprotective properties. The shift away from lithium was driven more by market forces and prescribing convenience than by evidence that alternatives were superior. A 2025 Springer paper titled “Lithium: Old Drug, New Tricks?” made this point explicitly, arguing that lithium’s decline reflected commercial pressures rather than clinical data.
What Does Low-Dose Lithium Mean for Brain Health and Dementia Prevention?
One of the most important developments in lithium’s comeback is the distinction between traditional therapeutic doses and low-dose or trace lithium. Traditional lithium therapy for bipolar disorder typically involves doses of 900 to 1,200 milligrams daily, requiring regular blood draws to monitor for toxicity and potential side effects including thyroid dysfunction, kidney issues, and tremor. Low-dose lithium — generally 300 to 450 milligrams — does not require blood monitoring and is well tolerated by most people. This is a fundamentally different risk-benefit calculation. Epidemiological studies have consistently shown that regions with higher natural lithium levels in drinking water have lower rates of both suicide and dementia. These are population-level observations, not clinical trials, but the pattern has held across multiple countries and study designs.
Surveys of people taking over-the-counter lithium orotate, which provides roughly 10 milligrams of elemental lithium daily, show consistent improvements in mood, anxiety, and irritability. An open-label study in severely depressed patients who had not responded to venlafaxine found significant benefits with low-dose lithium augmentation — a finding that matters for the many patients cycling through medications without adequate relief. The limitation here is important to acknowledge. Epidemiological correlation is not the same as causation, and over-the-counter supplement surveys lack the rigor of randomized controlled trials. Low-dose lithium orotate supplements are not FDA-regulated for these purposes, and quality control varies between manufacturers. Anyone considering lithium supplementation for cognitive protection should discuss it with their physician, particularly if they have kidney disease or thyroid conditions or are taking other medications that interact with lithium. The science is genuinely promising, but it has not yet reached the stage where blanket recommendations are appropriate.
How Does Lithium Compare to Other Approaches for Neuroprotection?
What sets lithium apart from most drugs being studied for Alzheimer’s prevention is that it has a clearly identified molecular mechanism — GSK3β inhibition — and 75 years of clinical safety data in humans. Most Alzheimer’s drug candidates are novel molecules with limited long-term safety profiles. The amyloid-targeting antibodies like lecanemab and donanemab, which received significant attention in recent years, work by clearing existing amyloid plaques but come with risks of brain swelling and microbleeds, require expensive infusions, and have shown only modest clinical benefits. Lithium, by contrast, appears to work upstream — preventing the pathological cascade before it starts. The trade-off is timing. Amyloid antibodies are designed for people who already have significant amyloid burden, while lithium’s neuroprotective benefits may be most relevant as a preventive strategy in people who are still cognitively healthy or in the earliest stages of decline.
Researchers now argue that lithium should be reconceptualized as a “disease-modifying drug” — one that affects bipolar disorder from the DNA and cellular level through brain structure and function, according to a 2025 Lancet Psychiatry paper. If this framing extends to Alzheimer’s, lithium could occupy a unique space as a cheap, well-understood, widely available preventive agent rather than a late-stage intervention. The cost comparison alone is staggering. Lithium is a generic medication that costs pennies per day. Lecanemab costs approximately $26,500 per year. For a disease that affects more than six million Americans and is projected to triple in prevalence by 2050, the public health implications of an effective, affordable preventive agent are difficult to overstate. That said, lithium’s neuroprotective benefits in humans remain to be proven in large-scale clinical trials, and no one should substitute it for evidence-based Alzheimer’s treatments without medical guidance.
Lithium and Suicide Prevention — The Evidence That Never Went Away
Even during the years when lithium prescriptions were declining, one body of evidence remained stubbornly consistent: lithium reduces suicide risk. Meta-analyses confirm that higher lithium levels in drinking water are associated with lower population suicide rates. Lithium is the only psychiatric medication with robust evidence for reducing suicide risk specifically — not just as a downstream effect of treating the underlying mood disorder, but as a direct anti-suicidal property. This distinction matters more than it might seem. Antidepressants treat depression, and treating depression can reduce suicidal ideation.
But lithium appears to reduce suicidal behavior even in patients whose mood symptoms are not fully controlled, suggesting a separate mechanism — possibly related to its effects on impulsivity, aggression, and emotional regulation. For families dealing with a loved one’s dementia, this is relevant because depression and suicidal ideation are common in early-stage cognitive decline, when patients are still aware enough to understand what is happening to them. The limitation is that the drinking water studies, while compelling in aggregate, involve trace amounts of lithium far below therapeutic doses, and it is not entirely clear how to translate population-level epidemiological findings into individual clinical recommendations. The suicide prevention evidence is strongest for lithium prescribed at therapeutic doses for bipolar disorder. Whether low-dose or trace lithium supplementation provides meaningful suicide prevention benefits for the general population is a question that remains open.
What the Expert Consensus Now Says About Lithium
A 2025 expert consensus study using the Delphi method — a structured process where leading specialists iteratively refine their positions — reaffirmed lithium as the gold standard for bipolar disorder management. The consensus emphasized that lithium significantly reduces the risk of new manic and depressive episodes compared to placebo, and that its benefits extend well beyond acute mood stabilization. The same year, the Springer review “Lithium: Old Drug, New Tricks?” catalogued emerging evidence for lithium’s neuroprotective and disease-modifying properties in conditions beyond bipolar disorder, including Alzheimer’s, traumatic brain injury, and stroke.
This renewed expert endorsement matters because clinical practice had drifted significantly from what the evidence actually supports. When only 25% of bipolar patients are receiving a first-line treatment that expert consensus and 75 years of data support, something has gone wrong in how medicine translates evidence into practice. The comeback is not lithium changing — it is the field finally reckoning with how far prescribing habits had strayed from the science.
Where Lithium Research Goes From Here
The active clinical trial investigating lithium for prevention of cognitive decline in mood disorder patients (NCT06662526) represents a critical next step. If it demonstrates efficacy, it could open the door to larger prevention trials in the general aging population.
The Nature study’s identification of lithium deficiency as a potential driver of Alzheimer’s pathology also raises the question of whether routine lithium level testing could become part of cognitive health screening, much as vitamin D and B12 levels are now commonly checked in older adults. The broader trajectory is toward precision — identifying who is most likely to benefit from lithium supplementation, at what dose, and at what stage of life or disease. The era of one-size-fits-all prescribing is giving way to more nuanced approaches, and lithium’s story may ultimately be less about a comeback than about finally understanding what the drug has been capable of all along.
Conclusion
Lithium’s reemergence in psychiatry is driven by converging lines of evidence — a landmark Nature study revealing lithium deficiency in Alzheimer’s brains, renewed expert consensus affirming its status as the gold standard for bipolar disorder, consistent epidemiological links between lithium and lower rates of suicide and dementia, and the practical appeal of low-dose formulations that avoid the monitoring burden of traditional therapy. After years of decline driven more by pharmaceutical marketing than by clinical evidence, lithium prescriptions are showing signs of stabilizing and even rebounding. For patients and families navigating brain health, the takeaway is not to self-medicate with lithium supplements but to have an informed conversation with a physician about whether lithium — at any dose — might be appropriate.
The science has moved faster than clinical practice, and many doctors, particularly in primary care, remain unfamiliar with lithium’s emerging neuroprotective profile. Asking the question is the first step. The clinical trials underway now will determine whether lithium becomes a cornerstone of Alzheimer’s prevention strategy, but the biological rationale is already compelling enough to warrant serious attention.
Frequently Asked Questions
Is lithium only used for bipolar disorder?
No. While lithium is best known as a mood stabilizer for bipolar disorder, emerging research shows potential neuroprotective benefits for Alzheimer’s disease and cognitive decline. It is also the only psychiatric medication with robust evidence for directly reducing suicide risk. Low-dose lithium is being studied for depression augmentation, anxiety, and irritability as well.
Is over-the-counter lithium orotate the same as prescription lithium?
They are not equivalent. Prescription lithium (typically lithium carbonate) is dosed at 900–1,200 mg daily and requires blood monitoring. Over-the-counter lithium orotate provides roughly 10 mg of elemental lithium daily — a fraction of the therapeutic dose. Surveys show mood and anxiety benefits from lithium orotate, but it has not been rigorously studied in randomized controlled trials for most conditions.
Can lithium prevent Alzheimer’s disease?
The evidence is promising but not yet conclusive in humans. The August 2025 Nature study showed that lithium deficiency accelerates Alzheimer’s pathology in animal models, and low-dose lithium orotate reversed disease markers in aging mice. Epidemiological studies link higher lithium in drinking water to lower dementia rates. A clinical trial (NCT06662526) is currently testing lithium for cognitive decline prevention in mood disorder patients.
Why did doctors stop prescribing lithium?
Lithium prescriptions declined due to aggressive marketing of newer atypical antipsychotics, the inconvenience of required blood monitoring, insufficient training in lithium management, and a general preference among some psychiatrists for newer medications. Primary care doctors are about 80% less likely than psychiatrists to prescribe it. This decline occurred despite lithium remaining a first-line treatment in international guidelines.
Is lithium safe for older adults?
Lithium can be used in older adults but requires careful management. Traditional therapeutic doses need regular blood monitoring due to risks of thyroid and kidney effects, and older adults are more susceptible to toxicity. Low-dose lithium (300–450 mg) does not typically require blood monitoring and is better tolerated. Any use should be supervised by a physician familiar with lithium management, especially in patients with kidney disease or those taking diuretics.
Does lithium in drinking water really reduce suicide and dementia rates?
Multiple meta-analyses across different countries have found consistent associations between higher natural lithium levels in drinking water and lower rates of both suicide and dementia at the population level. These are correlational findings, not proof of causation, but the consistency across studies and the known biological mechanisms — particularly GSK3β inhibition — make the association biologically plausible.
